Hikma Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Hikma Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 12.8% bzw. 3.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 15.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.1% betragen.
Wichtige Informationen
12.8%
Wachstumsrate der Gewinne
15.9%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 19.6% |
| Wachstumsrate der Einnahmen | 3.8% |
| Zukünftige Eigenkapitalrendite | 18.1% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 18 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark
Nov 11
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 3,320 | 523 | 542 | 817 | 8 |
| 12/31/2025 | 3,177 | 479 | 517 | 775 | 8 |
| 12/31/2024 | 3,039 | 443 | 352 | 552 | 8 |
| 6/30/2024 | 3,017 | 285 | 379 | 584 | N/A |
| 3/31/2024 | 2,946 | 238 | 392 | 596 | N/A |
| 12/31/2023 | 2,875 | 190 | 404 | 608 | N/A |
| 9/30/2023 | 2,803 | 168 | 389 | 596 | N/A |
| 6/30/2023 | 2,731 | 146 | 373 | 583 | N/A |
| 3/31/2023 | 2,624 | 167 | 344 | 557 | N/A |
| 12/31/2022 | 2,517 | 188 | 314 | 530 | N/A |
| 9/30/2022 | 2,534 | 267 | 325 | 557 | N/A |
| 6/30/2022 | 2,550 | 346 | 335 | 583 | N/A |
| 3/31/2022 | 2,552 | 384 | 372 | 611 | N/A |
| 12/31/2021 | 2,553 | 421 | 409 | 638 | N/A |
| 9/30/2021 | 2,489 | 444 | 294 | 517 | N/A |
| 6/30/2021 | 2,425 | 467 | 179 | 396 | N/A |
| 3/31/2021 | 2,383 | 449 | 210 | 430 | N/A |
| 12/31/2020 | 2,341 | 431 | 240 | 464 | N/A |
| 9/30/2020 | 2,317 | 472 | 306 | 521 | N/A |
| 6/30/2020 | 2,292 | 513 | 372 | 577 | N/A |
| 3/31/2020 | 2,250 | 500 | 329 | 525 | N/A |
| 12/31/2019 | 2,207 | 486 | 286 | 472 | N/A |
| 9/30/2019 | 2,173 | 424 | 283 | 452 | N/A |
| 6/30/2019 | 2,138 | 361 | 279 | 432 | N/A |
| 3/31/2019 | 2,104 | 322 | 285 | 431 | N/A |
| 12/31/2018 | 2,070 | 282 | 291 | 430 | N/A |
| 9/30/2018 | 2,045 | -262 | 275 | 417 | N/A |
| 6/30/2018 | 2,020 | -806 | 259 | 403 | N/A |
| 3/31/2018 | 1,978 | -824 | N/A | 423 | N/A |
| 12/31/2017 | 1,936 | -843 | N/A | 443 | N/A |
| 9/30/2017 | 1,950 | -338 | N/A | 431 | N/A |
| 6/30/2017 | 1,963 | 166 | N/A | 419 | N/A |
| 3/31/2017 | 1,957 | 161 | N/A | 356 | N/A |
| 12/31/2016 | 1,950 | 155 | N/A | 293 | N/A |
| 9/30/2016 | 1,782 | 166 | N/A | 317 | N/A |
| 6/30/2016 | 1,613 | 176 | N/A | 340 | N/A |
| 3/31/2016 | 1,527 | 214 | N/A | 353 | N/A |
| 12/31/2015 | 1,440 | 252 | N/A | 366 | N/A |
| 9/30/2015 | 1,450 | 248 | N/A | 358 | N/A |
| 6/30/2015 | 1,460 | 243 | N/A | 350 | N/A |
| 3/31/2015 | 1,475 | 261 | N/A | 388 | N/A |
| 12/31/2014 | 1,489 | 278 | N/A | 425 | N/A |
| 9/30/2014 | 1,477 | 293 | N/A | 413 | N/A |
| 6/30/2014 | 1,465 | 308 | N/A | 401 | N/A |
| 3/31/2014 | 1,415 | 260 | N/A | 369 | N/A |
| 12/31/2013 | 1,365 | 212 | N/A | 337 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: HIKDas prognostizierte Gewinnwachstum (12.8% pro Jahr) liegt über der Sparquote (2.1%).
Ertrag vs. Markt: HIKDie Erträge des Unternehmens (12.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt UK (14.6% pro Jahr).
Hohe Wachstumserträge: HIKDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: HIKDie Einnahmen des Unternehmens (3.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.5% pro Jahr).
Hohe Wachstumseinnahmen: HIKDie Einnahmen des Unternehmens (3.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: HIKDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.1%).